Objective: Evaluating effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on the urinary CKD273 proteomic score in patients with type 2 diabetes (T2D) and albuminuria.

Methods: A double-blinded, randomized, placebo-controlled, crossover trial of 12 weeks dapagliflozin (10 mg) or matching placebo added to standard care. Patients included (n=40) had T2D and albuminuria (UACR≥30 mg/g). At baseline and end of treatment periods HbA1C was measured, spot urine for urinary proteomics and three consecutive morning spot urines for albuminuria were collected and 24h blood pressure and 51Cr-EDTA (GFR) were performed. Urine proteomic patterns was evaluated using the CKD273 score. To determine high-risk or low risk of diabetic kidney disease a previously defined cut off of 0.154 was used. Results were compared using mixed model analysis adjusted for age, sex, systolic blood pressure, HbA1c, albuminuria and GFR. Chi-square analysis was used to examine change in risk category based on proteomics.

Results: Baseline values for the 36 participants completing the study: Geometric mean urinary albumin creatinine ratio (UACR) = 147 (IQR 82-330) mg/g, mean eGFR = 84 ml/minute/1.73 m2 (SD±19.3), HbA1c = 73 mmol/mol (SD±15) and 24h blood pressure = 147/82 mmHg (SD±12.0/8.1). Dapagliflozin reduced UACR by 44% (95% CI 17-78%, p<0.01), GFR by 10.6 (6-15) ml/minute/1.73m2 (p<0.01), HbA1c by 7.4 (5-10) mmol/mol (p<0.01) and 24h blood pressure by 4.1/2.9 mmHg (p=0.058/p<0.01). The CKD273 proteomic score improved from mean 0.457 with -0.217 (p<0.01) and renal risk category improved from 72% at high risk to 47% after dapagliflozin (p=0.032).

Conclusions: Dapagliflozin added to standard care in T2D patients with albuminuria significantly reduced the urinary CKD273 proteomic score and renal risk. This indicates a possible direct beneficial effect on the kidneys, which may explain part of the renal benefit of SGLT2i seen in clinical trials.

Disclosure

F. Persson: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk A/S. Research Support; Self; AstraZeneca, Sanofi. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi. M.K. Eickhoff: None. H. Mischak: Stock/Shareholder; Self; Mosaiques Diagnostics. M. Frimodt-Moller: None. P. Rossing: Advisory Panel; Self; AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc. Speaker's Bureau; Self; Eli Lilly and Company, Merck Sharp & Dohme Corp. Other Relationship; Self; Novartis AG, Novo Nordisk A/S.

Funding

AstraZeneca

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.